Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Bioinformatics and Molecular Docking Study of Amentoflavone and 3,8-Biapigenin as Inhibitors on Cervical Cancer Proteins

Indonesian Journal of Cancer Chemoprevention · Vol. 14 No. 2 (2023) · hlm. 105–116

DOI
10.14499/indonesianjcanchemoprev14iss2pp105-116
ISSN
2355-8989, 2088-0197
Terbit
2023-06-30
Penerbit
Indonesian Society for Cancer Chemoprevention
Bahasa
eng

Abstrak

Cervical cancer maintains its second-place ranking for Indonesia's highest number of cancer cases. In 2021, there were 36,633 cases of cervical cancer in Indonesia, with a rising death rate. Commonly, chemotherapy is used to treat cervical cancer and can improve the survival chances of patients, but these therapies imply increased toxicity. Biflavonoid group compounds like amentoflavone and 3,8-Biapigenin have the potential to act as anticancer agents by modulating multiple signaling pathways. This study aims to determine the cervical anticancer potential of amentoflavone and 3,8-Biapigenin based on in silico study. Prediction of anticancer activity in silico using Prediction of Activity Spectra for Active Substances (PASS) online, followed by target protein tracing using STITCH-STRING, then receptor analysis test using Ramachandran plot. A molecular docking test was conducted to determine the binding affinity of the compound with the receptor. Based on the online PASS, the compounds as thought to have low cervical anticancer potential if tested on a laboratory scale. STAT3, EP300, CYP1A1, and AKR1C1 proteins used in this study have met the requirements of a suitable receptor for molecular docking test. The best binding affinity was obtained at the interaction of amentoflavone and STAT3 with a better docking score (-9.3 kcal/mol) than doxorubicin (-7.1 kcal/mol). Overall, the results suggest biflavonoid compounds have the potential to be developed as a chemopreventive agent for cervical cancer.Keywords: bioinformatics, molecular docking, amentoflavone, 3,8-Biapigenin, cervical cancer protein.

Jaringan kolaborasi para penulis

21 penulis · 53 tautan kepenulisan bersama · 14 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Muhammadiyah University of Yogyakarta
  • Universitas Gadjah Mada
  • Sumatera Institute of Technology
  • Universitas Jember
  • Politeknik Kesehatan Bhakti Setya Indonesia
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Adi HermawansyahMuhammadiyah University of Yogyakarta4
Chaessy Yori AnggrainiMuhammadiyah University of Yogyakarta4
Nuha Haifa ArifinMuhammadiyah University of Yogyakarta2
Ivana Kinanti KenyoriMuhammadiyah University of Yogyakarta2
Alfiah AmaliyahMuhammadiyah University of Yogyakarta2
Rawi Ingra SavitriMuhammadiyah University of Yogyakarta1
Aji WinantaMuhammadiyah University of Yogyakarta1
Linta Sabila HanikMuhammadiyah University of Yogyakarta1
Endah PuspitasariUniversitas Jember1
Dyaningtyas Dewi Pamungkas PutriUniversitas Gadjah Mada1
Sarmoko SarmokoSumatera Institute of Technology1
Nur IsmiyatiPoliteknik Kesehatan Bhakti Setya Indonesia1
Aditya FitriasariUniversitas Gadjah Mada1
Vidia NoviyantiMuhammadiyah University of Yogyakarta1
Melany Ayu OctaviaMuhammadiyah University of Yogyakarta1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://ijcc.chemoprev.org/index.php/ijcc/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Bioinformatics and Molecular Docking Study of Amentoflavone and 3,8-Biapigenin as Inhibitors on Cervical Cancer Proteins</dc:title>
	<dc:creator>Ningrum, Dhecella Winy Cintya</dc:creator>
	<dc:creator>Kusumaningtyas, Triana Arum</dc:creator>
	<dc:creator>Febriansah, Rifki</dc:creator>
	<dc:creator>Juniananda, Melisa</dc:creator>
	<dc:creator>Tasminatun, Sri</dc:creator>
	<dc:creator>Krisridwany, Annisa</dc:creator>
	<dc:description xml:lang="en-US">Cervical cancer maintains its second-place ranking for Indonesia's highest number of cancer cases. In 2021, there were 36,633 cases of cervical cancer in Indonesia, with a rising death rate. Commonly, chemotherapy is used to treat cervical cancer and can improve the survival chances of patients, but these therapies imply increased toxicity. Biflavonoid group compounds like amentoflavone and 3,8-Biapigenin have the potential to act as anticancer agents by modulating multiple signaling pathways. This study aims to determine the cervical anticancer potential of amentoflavone and 3,8-Biapigenin based on in silico study. Prediction of anticancer activity in silico using Prediction of Activity Spectra for Active Substances (PASS) online, followed by target protein tracing using STITCH-STRING, then receptor analysis test using Ramachandran plot. A molecular docking test was conducted to determine the binding affinity of the compound with the receptor. Based on the online PASS, the compounds as thought to have low cervical anticancer potential if tested on a laboratory scale. STAT3, EP300, CYP1A1, and AKR1C1 proteins used in this study have met the requirements of a suitable receptor for molecular docking test. The best binding affinity was obtained at the interaction of amentoflavone and STAT3 with a better docking score (-9.3 kcal/mol) than doxorubicin (-7.1 kcal/mol). Overall, the results suggest biflavonoid compounds have the potential to be developed as a chemopreventive agent for cervical cancer.Keywords: bioinformatics, molecular docking, amentoflavone, 3,8-Biapigenin, cervical cancer protein.</dc:description>
	<dc:publisher xml:lang="en-US">Indonesian Society for Cancer Chemoprevention</dc:publisher>
	<dc:contributor xml:lang="en-US"></dc:contributor>
	<dc:date>2023-06-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US"></dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijcc.chemoprev.org/index.php/ijcc/article/view/464</dc:identifier>
	<dc:identifier>10.14499/indonesianjcanchemoprev14iss2pp105-116</dc:identifier>
	<dc:source xml:lang="en-US">Indonesian Journal of Cancer Chemoprevention; Vol 14, No 2 (2023); 105-116</dc:source>
	<dc:source>2355-8989</dc:source>
	<dc:source>2088-0197</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijcc.chemoprev.org/index.php/ijcc/article/view/464/286</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2023 Indonesian Journal of Cancer Chemoprevention</dc:rights>
</oai_dc:dc>